Rona Therapeutics showcased encouraging Phase 1 findings for RN0191, an innovative siRNA treatment aimed at PCSK9, during the 2024 AHA Scientific Sessions.

The global pain management market was valued at $79.4 billion in 2021 and is projected to grow to $120.7 billion by 2027, with a compound annual growth rate (CAGR) of 7.39%.

AbbVie has obtained approval from the European Commission for ELAHERE® (mirvetuximab soravtansine) to treat platinum-resistant ovarian cancer.

Pegaptanib, developed by EyeTech Pharmaceuticals and later acquired by OSI Pharmaceuticals, is a pegylated aptamer that targets VEGF.

Biosion has signed a global exclusive licensing deal with Aclaris Therapeutics for two promising immunology products that could be first-in-class and best-in-class.

Tocilizumab is a humanized monoclonal antibody that targets the interleukin-6 receptor (IL-6R).

Capstan Therapeutics showcases preclinical findings on its primary in vivo CAR-T candidate, CPTX2309, during the ACR Convergence 2024 event.

Polatuzumab Vedotin-Piiq, also known as Polivy, is an antibody-drug conjugate (ADC) developed by Genentech, a member of the Roche Group.

Neurogene has provided an update regarding its ongoing Phase 1/2 open-label clinical study assessing the NGN-401 gene therapy.

Nusinersen, developed by Biogen in collaboration with Ionis Pharmaceuticals, is an antisense oligonucleotide that targets the survival motor neuron 2 (SMN2) gene.

Adicet Bio reports the dosing of the initial lupus nephritis patient in its Phase 1 trial of ADI-001 for autoimmune conditions.

Olpasiran, a promising therapeutic agent, is a small interfering RNA (siRNA) developed by Arrowhead Pharmaceuticals.